The binding of CLEC-2 to podoplanin expressed on tumor cells triggers platelet activation, aggregation, and the release of bioactive molecules that support tumor cell survival, adhesion to the vascular endothelium, extravasation to distant metastatic sites, and subsequent tumor growth 21-23. Here, PDPN is linked to neoplasm.